Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

ABSTRACT: Transcriptional effects of Nutlin treatment in murine MA9 leukemia after loss of Gata2.

ORGANISM(S): Mus musculus

PROVIDER: GSE264720 | GEO | 2025/04/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

Project description:Transcriptional effects of Gata2 deletion in murine MA9 leukemia.

2025-04-30 | GSE265756 | GEO

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

Project description:RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias with Nutlin

| PRJNA1103844 | ENA

RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

Project description:RNA-seq of murine MA9 Gata2 f/f and Gata2 -/- (Gata2 KO) leukemias.

| PRJNA1104155 | ENA

Gata2 promotes drug resistance in Acute Myeloid Leukemia (AML)

Project description:In this study, we generated mouse models of MLL-AF9-driven AML (MA9) harboring conditional alleles for Gata2 gene to precisely investigate the role of Gata2 in drug resistance and progression of MLL-rearranged (MLL-r) AML. Our findings revealed a novel mechanism for Gata2 in blunting p53 mediated apoptosis via transcriptional repression of Rassf4, a regulator of Mdm2 protein stability.

2025-05-01 | GSE266623 | GEO

Gata2 promotes drug resistance in Acute Myeloid Leukemia (AML) [ChIP-Seq]

2025-04-30 | GSE264719 | GEO

GATA2 mutant transduction of murine hematopoietic stem cells

Project description:GATA2 mutant transduction of murine hematopoietic stem cells

2018-09-01 | GSE111328 | GEO

GATA2 mutant transduction of murine hematopoietic stem cells

Project description:GATA2 mutant transduction of murine hematopoietic stem cells

| PRJNA436636 | ENA

GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2- mutated MDS/AML

Project description:Although familial myelodysplasia and acute myeloid leukemia (MDS/AML) is rare, its true prevalence is likely underestimated due to wide variations in the age of onset, disease latency and outcome between and within families, with some mutation carriers remaining asymptomatic into late adulthood. Reduced penetrance is a notable feature of germline GATA2 p.Thr354Met pedigrees. In this study, we demonstrate that silencing of the wildtype (WT) GATA2 allele discriminates between symptomatic and asymptomatic carriers and is linked with allele-specific differences in DNA methylation and H3K4me3 promotor deposition, providing a molecular explanation for the clinical heterogeneity observed within a GATA2-mutated AML family.

2018-09-21 | GSE104570 | GEO

Comparison of mRNA expression profiles of 3q21q26 and 3q21q26::Gata2+/– mouse leukemic cells

Project description:The 3q21q26 mice harboring a transgene recapitulating GATA2 enhancer-drived EVI1 overexpression in inv(3)(q21q26) allele develop leukemia. Gata2 heterogenous deletion accelerates leukemogenesis of the 3q21q26 mice. To get insights into the couse of the acceleration of leukemogenesis, RNA-sequencing analysis was performed using B220+Gr1–cKit+ populations containing leukemia-initiating cells in bone marrows of leukemic 3q21q26 and 3q21q26::Gata2+/– mice.

2017-10-01 | GSE86460 | GEO

Anti-leukemia activity of bortezomib through GATA2-WT1 axis in acute myeloid leukemia

Project description:GATA2 is a transcription factor essential for hematopoietic differentiation and lymphatic system formation. High expression of GATA2 has been implicated in myelodysplastic syndrome and acute myeloid leukemia. Bortezomib has a good effect in MM. However, the mechanism of bortezomib possesses anti-self-renewal and leukemogenesis in AML is still unclear. Here, we reported that GATA2 and WT1 protein is degraded by bortezomib. The half-life of GATA2 mRNA was obviously shorter in Bortezomib-treated cells. Knockdown of GATA2 by small hairpin RNAs (shRNAs) has potential anti-leukemia activity in leukemic cells. Bortezomib inhibited cell proliferation and induced apoptotic death without activation of caspases pathway. Finally, bortezomib decreased xenograft tumor size in a xenograft leukemia mouse model, and prolonged the survival time in mouse C1498 AML model. Collectively, bortezomib might be a potential treatment for AML.

2021-11-14 | GSE188358 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data